Epelsiban

Epelsiban

File:Epelsiban structure.svg
Systematic (IUPAC) name
(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethylpyridin-3-yl)-2-(morpholin-4-yl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]piperazine-2,5-dione
Clinical data
Legal status	Non-regulated
Identifiers
CAS Number	872599-83-2 1159097-48-9 (besylate)
ATC code	None
PubChem	CID: 11634973
ChemSpider	9809717
KEGG	D10117 Y
Chemical data
Formula	C30H38N4O4
Molecular mass	518.6 g/mol
SMILES CC[C@H](C)[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=C(N=C(C=C2)C)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4
InChI InChI=1S/C30H38N4O4/c1-5-18(2)26-28(35)32-25(23-16-21-8-6-7-9-22(21)17-23)29(36)34(26)27(24-11-10-19(3)31-20(24)4)30(37)33-12-14-38-15-13-33/h6-11,18,23,25-27H,5,12-17H2,1-4H3,(H,32,35)/t18-,25+,26+,27+/m0/s1 Key:UWHCWRQFNKUYCG-QUZACWSFSA-N

Epelsiban (GSK-557,296-B) is an oral drug which acts as a selective, sub-nanomolar (Ki=0.13 nM) oxytocin receptor antagonist with >31000-fold selectivity over the related vasopressin receptors and is being developed by GlaxoSmithKline for the treatment of premature ejaculation in men. and as an agent to enhance embryo or blastocyst implantation in women undergoing embryo or blastocyst transfer associated with in vitro fertilization (IVF).

See also

• Atosiban
• Barusiban
• L-368,899
• L-371,257
• Retosiban